The hemoglobin a1c testing devices market size has grown rapidly in recent years. It will grow from $1.73 billion in 2023 to $1.93 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The expansion observed during the historical period can be credited to comprehensive diabetes management initiatives, ongoing innovation, enhancements in healthcare infrastructure, the adoption of preventive healthcare practices, and the prevailing trend of home healthcare.
The hemoglobin a1c testing devices market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated growth in the forecast period can be ascribed to the expansion of point-of-care testing, the rise in home testing and self-monitoring, a heightened focus on preventive healthcare, the growing aging population, and the expansion of healthcare accessibility. Key trends expected in the forecast period encompass continuous innovation and cost efficiency, an escalating prevalence of diabetes, a shift towards point-of-care testing, technological advancements, and the increasing prominence of home healthcare and self-monitoring.
The hemoglobin A1c testing devices market is anticipated to witness growth driven by the increasing prevalence of diabetes. Diabetes, a chronic metabolic disorder causing elevated blood glucose levels, necessitates effective monitoring and management. Hemoglobin A1c testing provides valuable information on average blood glucose levels, aiding in the diagnosis of type 2 diabetes, pre-diabetes, and diabetes management. Notably, data from the Centers for Disease Control and Prevention (CDC) in 2022 revealed that approximately 37.3 million people, equivalent to 11.3% of the United States population, were affected by diabetes. Globally, the International Diabetes Federation reported around 537 million adults with diabetes in December 2021, with three out of four cases concentrated in low- and middle-income countries. The escalating number of diabetes cases underscores the driving force behind the growth of the hemoglobin A1c testing devices market.
The growth of the hemoglobin A1c testing devices market is poised to benefit from the easy accessibility of point-of-care (POC) tests. Point-of-care testing involves conducting analyses at the patient's location, streamlining the diagnostic process. The convenience of POC tests enhances patient satisfaction by minimizing wait times for results. Portable hemoglobin A1c testing devices, categorized as POC tests, offer quick and accurate results in diverse settings, including medical offices, pharmacies, and homes. The World Health Organization (WHO) emphasizes the simplicity and accessibility of POC diagnostics, making them usable not only by laboratory professionals but also by other healthcare practitioners with basic training. Thus, the widespread availability of point-of-care tests is expected to be a driving force for the hemoglobin A1c testing devices market.
A prominent trend in the hemoglobin A1c testing devices market involves product innovations by major companies seeking to strengthen their market position. For instance, Trivitron Healthcare Pvt. Ltd., an India-based medical device company, introduced NANO H5 and NANO H110 in June 2021. These advanced diagnostic solutions, based on HPLC technology, deliver HbA1c results within 130 seconds. NANO H5 and NANO H110 are compact, automated HPLC analyzers utilizing ion exchange liquid chromatography to quantitatively determine glycated hemoglobin in human whole blood samples. The devices offer efficiency in processing varying sample sizes, catering to the needs of medium to large laboratories.
The integration of microfluidic immunofluorescence tests for hemoglobin A1c represents a strategic focus for major companies in the market. Microfluidic immunofluorescence (MIF) combines microfluidics and immunofluorescence principles to detect and quantify biomarkers in biological samples. LumiraDx Limited, a London-based diagnostics company, achieved CE Marking for its HbA1c test in May 2022. Utilized with the LumiraDx Platform, this test provides rapid results in under seven minutes, facilitating the monitoring of diabetic patients and the swift screening of individuals at risk. This integration of advanced technology underscores the commitment to innovation in the hemoglobin A1c testing devices market.
In October 2021, Tosoh Bioscience LLC, a US-based company specializing in liquid chromatography products, including Ion-Exchange HPLC HbA1c analyzers, acquired Semba Biosciences Inc for an undisclosed amount. This strategic acquisition aims to enhance Tosoh Bioscience LLC's portfolio in the bio-purification segment and consolidate its competitive position in the chromatography market. Semba Biosciences Inc, a US-based life science company, operates in capillary electrophoresis technology-based HbA1c testing devices, contributing to the expansion of Tosoh Bioscience LLC's offerings.
Major companies operating in the hemoglobin a1c testing devices market report are Arkray Inc, Abbott Laboratories, Polymer Technology Systems Inc, Bio-Rad Laboratories Inc, Menarini Group, F Hoffmann-La Roche AG, Semba Biosciences Inc, Siemens Healthineers AG, Tosoh Corporation, Trinity Biotech plc, Transasia Bio-Medicals Limited, Beckman Coulter Inc, Diazyme Laboratories Inc, EKF Diagnostics Holdings plc, HemoCue AB, OSANG Healthcare Co Ltd, Danaher, Bayer AG, Thermo Fisher Scientific Inc., PTS Diagnostics India Private Limited, Hoffmann-La Roche & Co., Nova Biomedical, Randox Laboratories Ltd., ACON Laboratories Inc., DiaSys Diagnostic Systems GmbH, Erba Mannheim, Green Cross Medical Science Corp., Infopia Co. Ltd., TaiDoc Technology Corporation, Werfen, Zhejiang Orient Gene Biotech Co. Ltd.
North America was the largest region in the hemoglobin A1c testing devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hemoglobin A1c testing devices market during the forecast period. The regions covered in the hemoglobin a1c testing devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemoglobin a1c testing devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Two primary types of hemoglobin A1c testing devices exist, benchtop devices and handheld devices. Benchtop devices are designed for convenient usage on a laboratory workbench. Employed in laboratories to assess blood sugar levels in patients, benchtop hemoglobin A1c testing devices make use of various technologies such as ion exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay, and others. These technologies find application in hospitals, pharmaceuticals, medical devices, and laboratory testing.
The hemoglobin a1c testing devices market research report is one of a series of new reports that provides hemoglobin a1c testing devices market statistics, including hemoglobin a1c testing devices industry global market size, regional shares, competitors with a hemoglobin a1c testing devices market share, detailed hemoglobin a1c testing devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin a1c testing devices industry. This hemoglobin a1c testing devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hemoglobin a1c testing devices market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated growth in the forecast period can be ascribed to the expansion of point-of-care testing, the rise in home testing and self-monitoring, a heightened focus on preventive healthcare, the growing aging population, and the expansion of healthcare accessibility. Key trends expected in the forecast period encompass continuous innovation and cost efficiency, an escalating prevalence of diabetes, a shift towards point-of-care testing, technological advancements, and the increasing prominence of home healthcare and self-monitoring.
The hemoglobin A1c testing devices market is anticipated to witness growth driven by the increasing prevalence of diabetes. Diabetes, a chronic metabolic disorder causing elevated blood glucose levels, necessitates effective monitoring and management. Hemoglobin A1c testing provides valuable information on average blood glucose levels, aiding in the diagnosis of type 2 diabetes, pre-diabetes, and diabetes management. Notably, data from the Centers for Disease Control and Prevention (CDC) in 2022 revealed that approximately 37.3 million people, equivalent to 11.3% of the United States population, were affected by diabetes. Globally, the International Diabetes Federation reported around 537 million adults with diabetes in December 2021, with three out of four cases concentrated in low- and middle-income countries. The escalating number of diabetes cases underscores the driving force behind the growth of the hemoglobin A1c testing devices market.
The growth of the hemoglobin A1c testing devices market is poised to benefit from the easy accessibility of point-of-care (POC) tests. Point-of-care testing involves conducting analyses at the patient's location, streamlining the diagnostic process. The convenience of POC tests enhances patient satisfaction by minimizing wait times for results. Portable hemoglobin A1c testing devices, categorized as POC tests, offer quick and accurate results in diverse settings, including medical offices, pharmacies, and homes. The World Health Organization (WHO) emphasizes the simplicity and accessibility of POC diagnostics, making them usable not only by laboratory professionals but also by other healthcare practitioners with basic training. Thus, the widespread availability of point-of-care tests is expected to be a driving force for the hemoglobin A1c testing devices market.
A prominent trend in the hemoglobin A1c testing devices market involves product innovations by major companies seeking to strengthen their market position. For instance, Trivitron Healthcare Pvt. Ltd., an India-based medical device company, introduced NANO H5 and NANO H110 in June 2021. These advanced diagnostic solutions, based on HPLC technology, deliver HbA1c results within 130 seconds. NANO H5 and NANO H110 are compact, automated HPLC analyzers utilizing ion exchange liquid chromatography to quantitatively determine glycated hemoglobin in human whole blood samples. The devices offer efficiency in processing varying sample sizes, catering to the needs of medium to large laboratories.
The integration of microfluidic immunofluorescence tests for hemoglobin A1c represents a strategic focus for major companies in the market. Microfluidic immunofluorescence (MIF) combines microfluidics and immunofluorescence principles to detect and quantify biomarkers in biological samples. LumiraDx Limited, a London-based diagnostics company, achieved CE Marking for its HbA1c test in May 2022. Utilized with the LumiraDx Platform, this test provides rapid results in under seven minutes, facilitating the monitoring of diabetic patients and the swift screening of individuals at risk. This integration of advanced technology underscores the commitment to innovation in the hemoglobin A1c testing devices market.
In October 2021, Tosoh Bioscience LLC, a US-based company specializing in liquid chromatography products, including Ion-Exchange HPLC HbA1c analyzers, acquired Semba Biosciences Inc for an undisclosed amount. This strategic acquisition aims to enhance Tosoh Bioscience LLC's portfolio in the bio-purification segment and consolidate its competitive position in the chromatography market. Semba Biosciences Inc, a US-based life science company, operates in capillary electrophoresis technology-based HbA1c testing devices, contributing to the expansion of Tosoh Bioscience LLC's offerings.
Major companies operating in the hemoglobin a1c testing devices market report are Arkray Inc, Abbott Laboratories, Polymer Technology Systems Inc, Bio-Rad Laboratories Inc, Menarini Group, F Hoffmann-La Roche AG, Semba Biosciences Inc, Siemens Healthineers AG, Tosoh Corporation, Trinity Biotech plc, Transasia Bio-Medicals Limited, Beckman Coulter Inc, Diazyme Laboratories Inc, EKF Diagnostics Holdings plc, HemoCue AB, OSANG Healthcare Co Ltd, Danaher, Bayer AG, Thermo Fisher Scientific Inc., PTS Diagnostics India Private Limited, Hoffmann-La Roche & Co., Nova Biomedical, Randox Laboratories Ltd., ACON Laboratories Inc., DiaSys Diagnostic Systems GmbH, Erba Mannheim, Green Cross Medical Science Corp., Infopia Co. Ltd., TaiDoc Technology Corporation, Werfen, Zhejiang Orient Gene Biotech Co. Ltd.
North America was the largest region in the hemoglobin A1c testing devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hemoglobin A1c testing devices market during the forecast period. The regions covered in the hemoglobin a1c testing devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemoglobin a1c testing devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Two primary types of hemoglobin A1c testing devices exist, benchtop devices and handheld devices. Benchtop devices are designed for convenient usage on a laboratory workbench. Employed in laboratories to assess blood sugar levels in patients, benchtop hemoglobin A1c testing devices make use of various technologies such as ion exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay, and others. These technologies find application in hospitals, pharmaceuticals, medical devices, and laboratory testing.
The hemoglobin a1c testing devices market research report is one of a series of new reports that provides hemoglobin a1c testing devices market statistics, including hemoglobin a1c testing devices industry global market size, regional shares, competitors with a hemoglobin a1c testing devices market share, detailed hemoglobin a1c testing devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin a1c testing devices industry. This hemoglobin a1c testing devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hemoglobin A1c Testing Devices Market Characteristics3. Hemoglobin A1c Testing Devices Market Trends and Strategies31. Global Hemoglobin A1c Testing Devices Market Competitive Benchmarking32. Global Hemoglobin A1c Testing Devices Market Competitive Dashboard33. Key Mergers and Acquisitions in the Hemoglobin A1c Testing Devices Market
4. Hemoglobin A1c Testing Devices Market - Macro Economic Scenario
5. Global Hemoglobin A1c Testing Devices Market Size and Growth
6. Hemoglobin A1c Testing Devices Market Segmentation
7. Hemoglobin A1c Testing Devices Market Regional and Country Analysis
8. Asia-Pacific Hemoglobin A1c Testing Devices Market
9. China Hemoglobin A1c Testing Devices Market
10. India Hemoglobin A1c Testing Devices Market
11. Japan Hemoglobin A1c Testing Devices Market
12. Australia Hemoglobin A1c Testing Devices Market
13. Indonesia Hemoglobin A1c Testing Devices Market
14. South Korea Hemoglobin A1c Testing Devices Market
15. Western Europe Hemoglobin A1c Testing Devices Market
16. UK Hemoglobin A1c Testing Devices Market
17. Germany Hemoglobin A1c Testing Devices Market
18. France Hemoglobin A1c Testing Devices Market
19. Italy Hemoglobin A1c Testing Devices Market
20. Spain Hemoglobin A1c Testing Devices Market
21. Eastern Europe Hemoglobin A1c Testing Devices Market
22. Russia Hemoglobin A1c Testing Devices Market
23. North America Hemoglobin A1c Testing Devices Market
24. USA Hemoglobin A1c Testing Devices Market
25. Canada Hemoglobin A1c Testing Devices Market
26. South America Hemoglobin A1c Testing Devices Market
27. Brazil Hemoglobin A1c Testing Devices Market
28. Middle East Hemoglobin A1c Testing Devices Market
29. Africa Hemoglobin A1c Testing Devices Market
30. Hemoglobin A1c Testing Devices Market Competitive Landscape and Company Profiles
34. Hemoglobin A1c Testing Devices Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
Hemoglobin A1c Testing Devices Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hemoglobin a1c testing devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hemoglobin a1c testing devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:1) By Type: Bench Top Device; Handheld Device
2) By Technology: Ion-Exchange HPLC; Immunoassay; Boronate Affinity Chromatography; Direct Enzymatic Assay; Other Technologies
3) By End Use: Hospitals; Pharmaceuticals; Medical Devices; Laboratory Testing
Companies Mentioned: Arkray Inc; Abbott Laboratories; Polymer Technology Systems Inc; Bio-Rad Laboratories Inc; Menarini Group
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Arkray Inc
- Abbott Laboratories
- Polymer Technology Systems Inc
- Bio-Rad Laboratories Inc
- Menarini Group
- F Hoffmann-La Roche AG
- Semba Biosciences Inc
- Siemens Healthineers AG
- Tosoh Corporation
- Trinity Biotech plc
- Transasia Bio-Medicals Limited
- Beckman Coulter Inc
- Diazyme Laboratories Inc
- EKF Diagnostics Holdings plc
- HemoCue AB
- OSANG Healthcare Co Ltd
- Danaher
- Bayer AG
- Thermo Fisher Scientific Inc.
- PTS Diagnostics India Private Limited
- Hoffmann-La Roche & Co.
- Nova Biomedical
- Randox Laboratories Ltd.
- ACON Laboratories Inc.
- DiaSys Diagnostic Systems GmbH
- Erba Mannheim
- Green Cross Medical Science Corp.
- Infopia Co. Ltd.
- TaiDoc Technology Corporation
- Werfen
- Zhejiang Orient Gene Biotech Co. Ltd.
Methodology
LOADING...